Country: European Union
Language: English
Source: EMA (European Medicines Agency)
melatonin
RAD Neurim Pharmaceuticals EEC SARL
N05CH01
melatonin
Psycholeptics
Sleep Initiation and Maintenance Disorders; Autistic Disorder
Slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.
Revision: 10
Authorised
2018-09-20
23 B. PACKAGE LEAFLET 24 PACKAGE LEAFLET: INFORMATION FOR THE USER SLENYTO 1 MG PROLONGED-RELEASE TABLETS SLENYTO 5 MG PROLONGED-RELEASE TABLETS melatonin For children and adolescents aged 2-18 READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD STARTS TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you or your child only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours or your child’s. - If you or your child gets any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Slenyto is and what it is used for 2. What you need to know before you or your child takes Slenyto 3. How to take Slenyto 4. Possible side effects 5. How to store Slenyto 6. Contents of the pack and other information 1. WHAT SLENYTO IS AND WHAT IT IS USED FOR WHAT SLENYTO IS Slenyto is a medicine that contains the active ingredient, melatonin. Melatonin is a hormone produced naturally by the body. WHAT IT IS USED FOR Slenyto is for use in CHILDREN AND ADOLESCENTS (2 to 18 years old) with AUTISM SPECTRUM DISORDER (ASD) and/or Smith-Magenis syndrome, a NEUROGENETIC DISEASE (inherited condition affecting the nerves and brain). Slenyto shortens the time it takes to fall asleep and lengthens the duration of sleep. IT IS FOR THE TREATMENT OF INSOMNIA (SLEEPLESSNESS) when a healthy sleeping routine (such as a regular bedtime and soothing sleeping environment) has not worked well enough. The medicine can help you or your child fall asleep and may help you or your child sleep for longer during the night. 2. WHAT YOU NEED TO KNOW BEFORE YOU OR YOUR CHILD TAKES SLENYTO DO NOT TAKE SLENYTO IF YOU OR YOUR CHILD - is allergic to melatonin or any of the other ingredients of this medicine (listed in section 6). WARNINGS Read the complete document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Slenyto 1 mg prolonged-release tablets Slenyto 5 mg prolonged-release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Slenyto 1 mg prolonged-release tablets Each prolonged-release tablet contains 1 mg melatonin. Excipient with known effect Each prolonged-release tablet contains lactose monohydrate equivalent to 8.32 mg lactose. Slenyto 5 mg prolonged-release tablets Each prolonged-release tablet contains 5 mg melatonin. Excipient with known effect Each prolonged-release tablet contains lactose monohydrate equivalent to 8.86 mg lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Prolonged- release tablet. Slenyto 1 mg prolonged-release tablets Pink, film coated, round, biconvex, 3 mm diameter tablets with no imprint. Slenyto 5 mg prolonged-release tablets Yellow, film coated, round, biconvex, 3 mm diameter tablets with no imprint. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended starting dose is 2 mg of Slenyto. If an inadequate response has been observed, the dose should be increased to 5 mg, with a maximal dose of 10 mg. Slenyto should be taken once daily, 0.5-1 hour before bedtime and with or after food. 3 Data are available for up to 2 years’ treatment. The patient should be monitored at regular intervals (at least every 6 months) to check that Slenyto is still the most appropriate treatment. After at least 3 months of treatment, the physician should evaluate the treatment effect and consider stopping treatment if no clinically relevant treatment effect is seen. If a lower treatment effect is seen after titration to a higher dose, the prescriber should first consider a down-titration to a lower dose before deciding on a Read the complete document